Galectin-3 as a Prognostic Biomarker of Left Ventricular Assist Device Implantation Outcomes

Area of Science:

• Cardiology
• Biomarker Research
• Medical Devices

Background:

• Left ventricular assist devices (LVADs) are crucial for end-stage heart failure management.
• Predicting outcomes like right heart failure (RHF) and adverse events post-LVAD implantation remains challenging.
• Galectin-3 is being investigated for its role in cardiac disease progression.

Purpose of the Study:

• To assess the prognostic potential of Galectin-3 in patients with LVADs.
• To evaluate Galectin-3's correlation with clinical outcomes, including RHF, hemocompatibility-related adverse events (HRAEs), and mortality.
• To determine if Galectin-3 improves existing risk scores for RHF prediction.

Main Methods:

• A cohort of 159 heart failure patients receiving LVADs (2012-2020) was analyzed.
• Galectin-3 levels were measured and correlated with hemodynamic data, RHF, HRAEs, mortality, and other clinical parameters.
• Galectin-3 was incorporated into Michigan-RVF and EUROMACS-RHF risk scores for comparative analysis.

Main Results:

• Galectin-3 significantly correlated with RHF, inotrope duration, ICU length of stay, BUN, creatinine, and pulmonary artery pulsatility index.
• Inclusion of Galectin-3 improved the predictive accuracy (c-statistic) for RHF in both Michigan-RVF (0.80-0.86) and EUROMACS-RHF (0.77-0.82) scores.
• Elevated Galectin-3 (>18.2 ng/mL) was significantly associated with HRAEs and mortality.

Conclusions:

• Galectin-3 demonstrates significant prognostic value in LVAD patients.
• This biomarker enhances the predictive capability of established risk scores for RHF.
• Galectin-3 holds promise as a valuable predictive biomarker for managing LVAD recipients.